Trial Profile
An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice-Daily in Subjects With Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs Clascoterone (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions; Registrational
- Sponsors Cassiopea
- 26 Jul 2023 Cosmos partner Sun Pharma expects first sales of Winlevi in Canada in Q4 2023.
- 20 Jun 2023 According to Cosmo Pharmaceuticals media release, Sun Pharmaceutical Industries Limited has received marketing authorization (Notice of Compliance) from Health Canada for Winlevi (clascoterone cream 1%) to target the hormonal component of acne for Canadian patients in 40 years.
- 21 Mar 2023 Results from CB03-01-25, CB03-01-26, CB03-01-27 assessing Safety , presented at the American Academy of Dermatology annual Meeting 2023